Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M
Viridian Therapeutics (NASDAQ: VRDN) has priced upsized concurrent public offerings totaling $350 million. The financing includes $225 million in 1.75% convertible senior notes due 2032 and an equity offering of over 7.3 million shares at $17.00 per share. Net proceeds will be used to repay debt, fund market expansion studies for its thyroid eye disease franchise, advance early-stage research, and support general working capital.
Viridian Therapeutics releases topline phase 3 TED data elegrobart
Viridian Therapeutics announced positive topline results from its phase 3 REVEAL-2 clinical trial for elegrobart, an investigational treatment for chronic thyroid eye disease (TED). The study met its primary and key secondary endpoints, demonstrating high statistical significance in proptosis responder rates and diplopia responder rates for both Q4W and Q8W dosing regimens. Viridian plans to submit a Biologics License Application (BLA) for elegrobart in Q1 2027, aiming for the first autoinjector treatment for both active and chronic TED.
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results
The article discusses Viridian Therapeutics (VRDN) as it approaches a PDUFA decision, indicating a significant regulatory milestone for the company. It highlights the company's progress in advancing its Thyroid Eye Disease (TED) pipeline, suggesting ongoing development and potential for new treatments. Additionally, Viridian Therapeutics has reported its Q1 results, providing financial and operational updates to stakeholders.
HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026 - News and Statistics
HighVista Strategies sold 238,243 shares of Viridian Therapeutics, valued at approximately $7.08 million, during Q1 2026 as revealed in a recent SEC filing. This divestment occurs as Viridian Therapeutics approaches a critical FDA decision deadline for its lead therapy, veligrotug, and has seen its stock rise by 35% over the past year. The company is a clinical-stage biotechnology firm focused on treatments for thyroid eye disease, with potential for a differentiated commercial approach with its subcutaneous candidate, elegrobart.
Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History
This article provides a comprehensive overview of Viridian Therapeutics Inc (VRDN) stock, including its current price, key statistics, recent news, financial data, and analyst forecasts. It highlights the company's focus on developing treatments for thyroid eye disease and includes details on stock performance, valuation metrics, and company debt. Recent news mentions both positive trial data and competitive pressures impacting the stock.
Bellevue Group (VRDN) files Schedule 13G for 6.6% ownership
Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, have jointly filed a Schedule 13G indicating a 6.6% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN). The filing reports shared voting and dispositive power over 6,726,144 shares of common stock, which represents 6.6% of the 102,458,094 shares deemed outstanding as of March 31, 2026. This passive investment disclosure highlights Bellevue's significant but non-controlling interest in Viridian Therapeutics.
Viridian Therapeutics stock (US92769V1044): Q1 earnings beat and Phase 3 data boost
Viridian Therapeutics reported a Q1 2026 EPS beat, with -0.90 USD against an estimated -1.06 USD. The company also announced positive Phase 3 results for its drug elegrobart in thyroid eye disease (TED) and raised $350 million in capital, strengthening its financial position. These developments position Viridian as a key player in the rare disease biotech market, with its lead candidate veligrotug currently under FDA Priority Review.
How Strong REVEAL-2 Data and Fresh Capital Raises Could Shape Viridian Therapeutics (VRDN) Investors
Viridian Therapeutics reported positive topline results from its REVEAL-2 phase 3 trial for elegrobart, indicating significant improvements for chronic thyroid eye disease, alongside completing two capital raises totaling US$350 million. This data strengthens Viridian's investment narrative by reinforcing its thyroid eye disease franchise with a potential at-home subcutaneous treatment, complementing its existing lead program, veligrotug, which is under FDA review. However, investors are cautioned to monitor the frequency and scale of capital raises and potential dilution risks, despite the promising clinical results.
Fairmount Healthcare Fund II invests $20m in Viridian Therapeutics By Investing.com
Fairmount Healthcare Fund II L.P. recently invested nearly $20 million in Viridian Therapeutics, acquiring 1,176,470 shares at $17.0 per share. This transaction increases their indirect stake to over 5 million shares, making them a significant owner with a board presence through Tomas Kiselak. The investment follows Viridian's positive clinical trial results for its thyroid eye disease drug and successful public offerings, leading to increased price targets from RBC Capital and Jefferies.
Fairmount-linked fund boosts Viridian (VRDN) stake with 1.18M-share open-market buy
Fairmount Healthcare Fund II L.P. has significantly increased its stake in Viridian Therapeutics (VRDN) by purchasing 1,176,470 shares of common stock at $17.00 per share in an open-market transaction on May 11, 2026. This acquisition brings the fund's total indirect holdings in Viridian to 5,090,928 shares. Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC, which have voting and investment power, disclaim beneficial ownership except to the extent of their pecuniary interest.
Viridian Therapeutics stock (US92769V1044): Q1 beat with 95.8% revenue surge
Viridian Therapeutics (VRDN) reported strong Q1 2026 earnings, beating EPS estimates by $0.16 with an EPS of -$0.90, and seeing a 95.8% year-over-year revenue surge to $0.14 million, exceeding forecasts. The biotech firm is advancing its pipeline in thyroid eye disease (TED), with BLA submission for its lead candidate, veligrotug, anticipated in Q1 2027. Despite current losses as a clinical-stage company, projected earnings growth signals improving fundamentals and potential for US market impact.
Viridian Therapeutics, Inc. Bonds — Corporate Bond Rates
This article provides a list of corporate bonds for Viridian Therapeutics, Inc., sorted by yield to worst. It highlights the stability of bonds as an investment during market volatility and offers key financial details such as yield, price, coupon, maturity date, and outstanding amount for a specific bond. Investors are encouraged to study these metrics to find reliable investments.
Viridian Therapeutics Raises $359 Million in Offerings
Viridian Therapeutics has successfully raised approximately $359 million through a combination of convertible senior notes and an equity offering. The company issued $250 million in 1.75% Convertible Senior Notes due 2032 and raised roughly $117 million from an offering of 7.35 million common shares at $17.00 each. This capital will be used to repay debt, fund market expansion studies for its thyroid eye disease franchise, and advance its earlier-stage R&D pipeline.
[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event
Viridian Therapeutics, Inc. (VRDN) has filed an 8-K report detailing two significant financing events: the issuance of $250 million in 1.75% Convertible Senior Notes due 2032 and a public equity offering of 7,352,942 common shares at $17.00 per share. The combined net proceeds of approximately $359 million are intended to repay outstanding debt, fund market expansion studies for its thyroid eye disease franchise, and advance earlier-stage R&D. These actions significantly shift the company's capital structure towards unsecured senior debt and additional equity.
Number of shareholders of Viridian Therapeutics, Inc. – NASDAQ:VRDN
This article provides details on the number of shareholders for Viridian Therapeutics, Inc. (NASDAQ: VRDN). It presents financial information related to the company, indicating changes in values and percentages over a period. The content is hosted on TradingView, a platform offering market data and financial tools.
Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings
This article reassesses Viridian Therapeutics (VRDN) after significant share price fluctuations. Using a Discounted Cash Flow (DCF) analysis, the stock appears 90.2% undervalued, with an estimated intrinsic value of $173.25 per share against a current price of $16.97. However, its Price-to-Sales (P/S) ratio of 24.66x is significantly higher than the industry average, suggesting it is overvalued by this metric, prompting investors to consider various valuation narratives.
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow (NASDAQ:VRDN)
Viridian Therapeutics (VRDN) has released positive top-line results from its REVEAL-2 Phase III trial for chronic Thyroid Eye Disease. The company also reported its Q1 2026 earnings, with an EPS of -$0.90 beating estimates by $0.18 and revenue of $141.00K, exceeding expectations by $113.25K and showing a 95.83% year-over-year growth. This article presents a slideshow in conjunction with these results.
Deep Track files 5.30% stake in Viridian Therapeutics (NYSE: VRDN) as Schedule 13G
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G indicating a 5.30% passive investment stake in Viridian Therapeutics (NYSE: VRDN). The filing reports beneficial ownership of 5,417,660 shares with shared voting and dispositive power. The percentage is calculated based on 102,206,571 shares outstanding as of February 20, 2026, and does not suggest a change in control.
Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings
This article reassesses Viridian Therapeutics (VRDN) following significant share price volatility, including recent gains but a year-to-date decline. Simply Wall St uses a 6-point valuation checklist, with the company scoring 2 out of 6, and explores two valuation methods: Discounted Cash Flow (DCF), which suggests the stock is 90.2% undervalued, and Price vs Sales (P/S), which indicates it is overvalued compared to industry averages and its proprietary "Fair Ratio." The article also introduces "Narratives" for a more personalized valuation approach.
Viridian Therapeutics (VRDN) Announces $350M Public Offerings for Growth Initiatives
Viridian Therapeutics (VRDN) has announced upsized public offerings totaling $350 million, comprising convertible senior notes and common stock. The proceeds, approximately $334.7 million, are designated for debt repayment, market expansion for thyroid eye disease, and advancing pipeline programs. While the company exhibits strong liquidity and growth potential, its profitability remains a significant challenge, resulting in a moderate GF Score™ of 65/100.
Why Viridian Therapeutics (VRDN) Is Up 31.8% After Positive Phase 3 Eye Drug Data and New Financing
Viridian Therapeutics (VRDN) shares rose after reporting positive Phase 3 data for elegrobart in chronic thyroid eye disease, alongside increased Q1 2026 net losses and new financing. The company is preparing for potential commercialization of veligrotug, with an upcoming FDA decision expected by June 30. Despite ongoing losses and dilution-prone financing, the successful trial data and launch readiness are seen as key catalysts, shifting investor focus from trial readouts to regulatory approval and market execution.
Viridian Therapeutics, Inc. (referred to as Viridian Therapeutics) officially announces the latest pricing details for its concurrent public offering program.
Viridian Therapeutics, Inc. has announced the pricing details for its concurrent public offering program, which includes 1.75% convertible senior notes due 2032 and common stock. The company has increased the size of the issuance, raising a total of $350 million from these two offerings. This announcement provides investors with the updated financial specifics of the offering.
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics announced the pricing of upsized concurrent public offerings, totaling $350.0 million in aggregate gross proceeds. These offerings include $225.0 million of 1.75% convertible senior notes due 2032 and 7,352,942 shares of common stock at $17.00 per share. The company plans to use the net proceeds to repay existing debt, fund market expansion studies for its thyroid eye disease franchise, advance its earlier pipeline, and for general corporate purposes.
Viridian Therapeutics prices upsized $350M concurrent stock and convertible notes offerings
Viridian Therapeutics has priced upsized concurrent offerings of common stock and convertible senior notes, aiming to raise a total of $350 million. The offerings include 7 million shares of common stock at $17.50 per share and $225 million in 3.50% convertible senior notes due 2031. The company has also granted underwriters options to purchase additional shares and notes.
Why Viridian Therapeutics (VRDN) Is Up 31.8% After Positive Phase 3 Eye Drug Data and New Financing
Viridian Therapeutics (VRDN) saw its stock rise by 31.8% following positive Phase 3 data for its eye drug elegrobart and new financing initiatives including convertible notes and an equity offering. The company reported a Q1 2026 net loss of US$104.9 million alongside modest revenue, highlighting its reliance on external funding. Viridian is positioning itself for potential commercialization in thyroid eye disease, with an upcoming FDA decision for veligrotug, which introduces both opportunities and risks related to regulatory approval and market uptake.
Viridian Therapeutics, Inc. (referred to as Viridian Therapeutics) officially announces the latest pricing details for its concurrent public offering program.
Viridian Therapeutics, Inc. has announced the updated pricing for its concurrent public offering program. The offering, which includes 1.75% convertible senior notes due 2032 and common stock, has been increased from its original plan. The company expects to raise a total of $350 million from these two offerings after adjustments.
Viridian Therapeutics’ stock up 35% after Phase III TED data release
Viridian Therapeutics' stock surged 35% after its REVEAL-2 Phase III trial for elegrobart in chronic thyroid eye disease (TED) met its primary and key secondary endpoints. This successful readout, following a previous positive trial, puts Viridian on track to submit a Biologics License Application (BLA) for elegrobart to the FDA in Q1 2027, aiming to offer a convenient at-home treatment for TED. The company anticipates facing competition from Amgen's Tepezza, which generated $1.9 billion in sales in 2025.
Viridian Therapeutics (NASDAQ: VRDN) offers $100M equity; REVEAL-2 meets primary endpoints
Viridian Therapeutics is offering $100 million in common stock and Series B non-voting convertible preferred stock, alongside a concurrent $150 million offering of convertible senior notes. The company also announced that topline results from its REVEAL-2 Phase 3 clinical trial for elegrobart met primary and key secondary endpoints with high statistical significance, supporting a planned Biologics License Application (BLA) submission in Q1 2027. Proceeds from these offerings are intended to repay debt, fund market expansion studies for its Thyroid Eye Disease (TED) franchise, and advance its pipeline.
Viridian Therapeutics (NASDAQ: VRDN) files $150M convertible note offering; REVEAL‑2 topline wins
Viridian Therapeutics has filed a $150 million convertible senior note offering, with an option for underwriters to purchase an additional $22.5 million. The company plans to use the proceeds, combined with a concurrent $100 million equity offering, to repay a secured loan, fund market expansion studies for its TED (Thyroid Eye Disease) franchise, and advance R&D. Separately, Viridian announced positive topline results from its REVEAL-2 Phase 3 trial for elegrobart, meeting primary and key secondary endpoints, and anticipates a Biologics License Application (BLA) submission in Q1 2027.
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Therapeutics has commenced concurrent public offerings of $150.0 million in convertible senior notes due 2032 and $100.0 million in common stock and Series B non-voting convertible preferred stock. The company plans to use the net proceeds to repay debt, fund market expansion studies for its TED franchise, advance its earlier pipeline, and for general corporate purposes. The offerings are subject to market conditions and may not both close.
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Viridian Therapeutics has announced proposed concurrent underwritten public offerings consisting of $150.0 million in convertible senior notes due 2032 and $100.0 million in common stock or Series B non-voting convertible preferred stock. The company intends to use the net proceeds to repay outstanding debt, fund market expansion studies for its TED franchise, and advance its earlier pipeline research and development. Jefferies, Leerink Partners, and Goldman Sachs are acting as joint book-running managers for these offerings.
Viridian soars on top-line phase 3 data for elegrobart in thyroid eye disease
Viridian Therapeutics (VRDN) surged approximately 34% after reporting positive top-line Phase 3 data for its thyroid eye disease drug, elegrobart. The drug, a monoclonal antibody targeting IGF-1R, successfully met its primary endpoint of proptosis responder rate. This significant clinical trial result led to a substantial increase in the company's stock value.
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Viridian Therapeutics reported its Q1 2026 financial results, highlighting that it is launch-ready for veligrotug, with a PDUFA target action date of June 30, 2026, for thyroid eye disease (TED). The company also announced positive Phase 3 data for subcutaneous elegrobart in both active and chronic TED, anticipating a BLA submission in Q1 2027. Additionally, Viridian is advancing its FcRn inhibitor portfolio and TSHR program, maintaining a strong cash position of $762.2 million as of March 31, 2026.
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q1 Revenue $141,000
Viridian Therapeutics, Inc. (VRDN) announced its Q1 revenue reached $141,000. This financial update follows several recent analyst adjustments and news regarding its Thyroid Eye Disease (TED) franchise and related clinical trials. The company is actively developing multiple candidates for serious and rare diseases, including its VRDN-001 and VRDN-003 for TED.
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Viridian Therapeutics announced positive topline results from its Phase 3 REVEAL-2 clinical trial for elegrobart in chronic Thyroid Eye Disease (TED). The study met its primary endpoint, with elegrobart demonstrating highly statistically significant proptosis responder rates and significant diplopia responder rates compared to placebo. Elegrobart, a subcutaneous treatment, was generally well tolerated, and the company plans for a BLA submission in Q1 2027, with the potential to be the first autoinjector treatment for TED.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Brokerages
Viridian Therapeutics (NASDAQ:VRDN) has received a "Moderate Buy" consensus rating from analysts, with 13 buy, 1 hold, and 1 sell rating, and an average 12-month price target of $37.07. Despite recent price target reductions by several brokerages, institutional investors have increased their holdings. The company recently missed quarterly EPS and revenue estimates and remains unprofitable.
Jennison Associates LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN
Jennison Associates LLC has made a new investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN), purchasing over 1.15 million shares valued at approximately $35.9 million, representing a 1.21% ownership stake. Despite this institutional interest and a "Moderate Buy" average analyst rating with an average target price of $37.07, the stock is trading significantly lower, and the company recently reported a disappointing financial quarter with missed earnings and revenue estimates.
Pictet Asset Management Holding SA Sells 126,618 Shares of Viridian Therapeutics, Inc. $VRDN
Pictet Asset Management Holding SA has reduced its stake in Viridian Therapeutics (NASDAQ: VRDN) by 12.1%, selling 126,618 shares. This move followed a significant earnings miss by Viridian, which reported lower-than-expected revenue and a net loss. Despite target price cuts from some firms, analysts still rate VRDN as a "Moderate Buy" with a consensus price target of $37.07, while the stock trades around $13.48.
Viridian Therapeutics (Nasdaq:VRDN) - Stock Analysis
This report provides a detailed stock analysis of Viridian Therapeutics (NASDAQ: VRDN), highlighting it as 59.8% undervalued despite a volatile share price. The company is currently unprofitable but revenue is forecast to grow significantly, driven by developments in treatments for rare diseases like Thyroid Eye Disease. Recent news includes a cut in consensus estimates for 2026, a decrease in price target, and positive topline results for one of its clinical trials.
Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN)
Truist has reiterated a Buy rating for Viridian Therapeutics (VRDN), despite lowering its price target from $36 to $33, citing over 140% upside potential. Wedbush also maintained an Outperform rating but reduced its target to $31, advising caution due to Amgen's recent pipeline update. Viridian Therapeutics, which develops treatments for rare illnesses, is anticipating positive REVEAL-2 clinical results for elegrobart in Q2 2026, which is expected to be a major catalyst.
CapEx per share of Viridian Therapeutics, Inc. – FWB:1S1
This page provides information on the Capital Expenditures (CapEx) per share for Viridian Therapeutics, Inc. (FWB:1S1) listed on the Frankfurt Stock Exchange. It includes details such as period, value, and change, with market data provided by ICE Data Services and reference data by FactSet. The article is primarily a data page within a financial platform, showing financial metrics for the company.
Truist Adjusts Viridian Therapeutics Price Target Amid Sector Shifts
Truist has lowered its price target for Viridian Therapeutics (NASDAQ: VRDN) to $36 from $40, while maintaining a Buy rating. This adjustment follows a broader sector analysis noting decreased reactivity to policy changes and an increase in deal activity within the biotech industry. Analysts tempered expectations for Viridian's commercial pipeline, projecting peak revenues for its thyroid eye disease (TED) treatments "Veli" at $630 million in 2031 and "Ele" at $1.14 billion in 2035, acknowledging competition from Amgen.
Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $33.00 by Analysts at Truist Financial
Truist Financial has lowered its price target for Viridian Therapeutics (NASDAQ:VRDN) from $36.00 to $33.00, though it maintains a "buy" rating, indicating a significant potential upside. Despite this and similar adjustments from other firms, the consensus analyst rating remains a "Moderate Buy" with an average price target of $37.07. The company recently missed quarterly EPS and revenue expectations and continues to show unprofitability with a negative EPS outlook.
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know
Kopp Family Office reduced its stake in Viridian Therapeutics by 117,878 shares, valued at $3.5 million, during the first quarter. This trim, which lowered Viridian's representation in Kopp's portfolio from 3.4% to 0.7% of AUM, is viewed as portfolio discipline rather than a loss of conviction, especially given recent competitive challenges from Amgen and a significant drop in Viridian's stock price. Despite Viridian being a clinical-stage biotech nearing an FDA decision for its lead therapy, the updated competitive landscape highlights the volatility of investing in this sector.
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $33
Truist Financial has reiterated its Buy rating on Viridian Therapeutics (VRDN.US) but has lowered its price target to $33. This adjustment reflects an updated valuation for the company.
Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026
Analysts have significantly revised down their 2026 revenue estimates for Viridian Therapeutics, Inc. (NASDAQ:VRDN) and increased their loss per share forecasts. The consensus now anticipates a 17% decline in sales, contrasting sharply with the company's historical growth, and expects the company to perform worse than the overall industry. Despite the negative revisions, the consensus price target remained largely unchanged, suggesting analysts don't foresee a long-term impact on valuation from the weaker earnings outlook.
Truist Cuts PT on Viridian Therapeutics (VRDN) to $36 From $40
Truist has lowered its price target for Viridian Therapeutics (VRDN) to $36 from $40, while maintaining a Buy rating. This adjustment is part of a broader research note previewing Q1 earnings in Biotech, where Truist observed easing reactivity to regulatory shifts and an increase in deal activity. Despite the tempered commercial opportunity expectations for Viridian's TED treatments, the firm acknowledges the ongoing debate regarding their real-world utility compared to established competitors.
Truist Cuts PT on Viridian Therapeutics (VRDN) to $36 From $40
Truist has lowered its price target on Viridian Therapeutics (VRDN) to $36 from $40, while maintaining a Buy rating. This adjustment comes as part of a Q1 earnings preview for Biotech, with Truist noting a tempering of expectations for Viridian's commercial opportunities in TED, though anticipating continued debate among investors and doctors regarding the company's therapeutic burden value proposition against competitors. Viridian Therapeutics is focused on developing therapies for autoimmune and rare diseases, including late-stage treatments for thyroid eye disease.
Will Amgen’s Subcutaneous Tepezza Success Reshape Viridian Therapeutics' (VRDN) Thyroid Eye Disease Narrative?
Amgen's positive Phase 3 results for a subcutaneous version of Tepezza in thyroid eye disease are impacting Viridian Therapeutics (VRDN), raising questions about its competitive position. While Viridian's veligrotug is undergoing Priority Review, the convenience of subcutaneous Tepezza could affect Viridian's market share and pricing power. Investors are urged to consider various expert opinions and Viridian's financial health, as the company remains unprofitable with a history of dilution.
Will Amgen’s Subcutaneous Tepezza Success Reshape Viridian Therapeutics' (VRDN) Thyroid Eye Disease Narrative?
Amgen's positive Phase 3 results for a subcutaneous version of Tepezza in thyroid eye disease have intensified the competitive landscape for Viridian Therapeutics (VRDN). This development places pressure on Viridian's veligrotug pipeline, requiring it to carve out a distinct space in the evolving treatment market. Investors are now closely scrutinizing Viridian's ability to demonstrate a "best-in-class" profile and secure funding, especially given its current unprofitability and history of shareholder dilution.
